Demonstration of potent lipid-lowering activity by a thyromimetic agent devoid of cardiovascular and thermogenic effects-Reference-Cited by-同舟云学术

Demonstration of potent lipid-lowering activity by a thyromimetic agent devoid of cardiovascular and thermogenic effects

Published:1996-09 Issue:1 Volume:126 Page:53-63
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Stephan Zouhair F.,Yurachek Edna C.,Sharif Robin,Wasvary Jong M.,Leonards Kenneth S.,Hu Chii-Whei,Hintze Thomas H.,Steele Ronald E.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Role of lipids and lipoprotein fractions in assessing atherogenesis. The Framingham Study;Kannel;Prog Lipid Res,1981

2. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering;Lipid Research Clinics Program;J Am Med Assoc,1984

3. Current therapy for hypercholesterolemia;Blum;J Am Med Assoc,1989

4. Regulatory role of triiodothyronine in the degradation of low density lipoprotein by cultured human skin fibroblasts;Chait;J Clin Endocrinol Metab,1979

5. The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 125I-low density lipoprotein in hypothyroidism and thyrotoxicosis;Walton;Clin Sci,1965

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conferring liver selectivity to a thyromimetic using a novel nanoparticle increases therapeutic efficacy in a diet-induced obesity animal model;PNAS Nexus;2023-08-01

2. Selective Thyromimetics Using Receptor and Tissue Selectivity Approaches: Prospects for Dyslipidemia;Journal of Medicinal Chemistry;2012-05-01

3. Thyroid Hormones and Thyromimetics;Burger's Medicinal Chemistry and Drug Discovery;2010-09-15

4. Nuclear Receptors as Targets in Cardiovascular Diseases;Methods and Principles in Medicinal Chemistry;2008-08-20

5. Development of the Thyroid Hormone Receptor β-Subtype Agonist KB-141 : A Strategy for Body Weight Reduction and Lipid Lowering with Minimal Cardiac Side Effects;Cardiovascular Drug Reviews;2006-06-07